Regeneron Pharmaceuticals, INC Form 4 insider transactions

Regeneron's CEO, Leonard Schleifer, sold 787 shares of company stock at an average price of $1,015.02 per share, executed under a pre-arranged 10b5-1 trading plan.

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 5, 2024, under a pre-arranged 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Regeneron Pharmaceuticals Director Michael S. Brown exercised stock options and sold shares of common stock on May 28, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,865 shares of common stock at $994.90 per share under a pre-arranged 10b5-1 trading plan.

Regeneron's CEO, Leonard Schleifer, executed sales of company stock on May 17, 2024, under a pre-arranged 10b5-1 trading plan.

George Yancopoulos, President and CSO of Regeneron Pharmaceuticals, sold shares of common stock on May 16, 2024, under a pre-arranged 10b5-1 trading plan.

George Yancopoulos, President and CSO of Regeneron Pharmaceuticals, sold shares of the company's common stock on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Regeneron's CEO, Leonard S. Schleifer, exercised stock options and sold shares between May 13 and May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Director George L. Sing exercised stock options and disposed of shares of Regeneron Pharmaceuticals on May 3, 2024.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 250 shares of common stock on May 1, 2024, at a price of $889.41 per share, according to a Form 4 filing with the SEC.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals (REGN) on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, reported the disposition of shares to a GRAT and acquisition of shares by his children.

George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, Inc., reported the sale of 16,848 shares of common stock at $900 per share on January 2, 2024, according to a Form 4 filing.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 250 shares of common stock on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Regeneron's EVP of Research, Andrew Murphy, exercised stock options and sold shares of common stock on March 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Director Arthur F. Ryan of Regeneron Pharmaceuticals sold a portion of his common stock holdings on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, reports the sale of 358 shares of common stock at $967.5 per share on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,000 shares of common stock on February 26, 2024.

Director George L. Sing reports exercising stock options and selling shares of Regeneron Pharmaceuticals on February 26, 2024.

Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, reported a gift of 1,020 shares of common stock and changes in beneficial ownership, including holdings in a 401(k) plan and spousal trust.